Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Kanta Subbarao and Keith Chappell.
Kanta Subbarao
Connection Strength
0.470
Keith Chappell
  1. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2021 10; 21(10):1383-1394.
    View in: PubMed
    Score: 0.235
  2. Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clin Transl Immunology. 2021; 10(4):e1269.
    View in: PubMed
    Score: 0.235
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.